In intention-to-treat analysis , no reduction in the risk of CVD or secondary CVD outcomes was seen for the DHA+EPA ( primary outcome : hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @-@ @ ) or lutein + zeaxanthin ( primary outcome : HR , @ ; @ % CI , @-@ @ ) groups .